On September 19, 2024, a Schedule 13G filing was made with the SEC, indicating that Ionic Ventures LLC, Ionic Management LLC, Brendan O'Neil, and Keith Coulston (collectively referred to as the Reporting Persons) have collectively acquired a significant stake in Vivos Therapeutics, Inc. The filing reveals that the Reporting Persons hold a shared voting and dispositive power over 412,064 shares of Vivos Therapeutics' common stock, which represents 8.7% of the company's total outstanding shares. The shares are beneficially owned by Ionic Ventures LLC and may be deemed to be beneficially owned by the other Reporting Persons due to shared power to vote and dispose of the shares. The principal business address for all Reporting Persons is in San Francisco, California. The filing was made pursuant to Rule 13d-1(b) and includes a joint filing agreement. The Reporting Persons have stated that the acquisition of the shares is not for the purpose of changing or influencing the control of Vivos Therapeutics, Inc.

On September 19, 2024, a Schedule 13G filing was made with the SEC, indicating that Ionic Ventures LLC, Ionic Management LLC, Brendan O'Neil, and Keith Coulston (collectively referred to as the Reporting Persons) have collectively acquired a significant stake in Vivos Therapeutics, Inc. The filing reveals that the Reporting Persons hold a shared voting and dispositive power over 412,064 shares of Vivos Therapeutics' common stock, which represents 8.7% of the company's total outstanding shares. The shares are beneficially owned by Ionic Ventures LLC and may be deemed to be beneficially owned by the other Reporting Persons due to shared power to vote and dispose of the shares. The principal business address for all Reporting Persons is in San Francisco, California. The filing was made pursuant to Rule 13d-1(b) and includes a joint filing agreement. The Reporting Persons have stated that the acquisition of the shares is not for the purpose of changing or influencing the control of Vivos Therapeutics, Inc.